2024
Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study
McEntegart M, Gonzalo N, Fendelander L, West N, Lansky A. Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study. Journal Of The Society For Cardiovascular Angiography & Interventions 2024, 3: 102289. DOI: 10.1016/j.jscai.2024.102289.Peer-Reviewed Original ResearchCoronary artery diseaseCalcified coronary artery diseasePercutaneous coronary interventionTarget lesion failureCoronary intravascular lithotripsyArtery diseaseFemale patientsIntravascular lithotripsySubcohort analysis of patientsPrevalence of coronary artery calcificationEnd pointsOptical coherence tomography imagesComposite of cardiac deathClinical events committeeSafety end pointAnalysis of patientsIndependent core laboratoryIncreased risk of mortalityIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionTarget lesion revascularizationCoronary artery calcificationEffectiveness end pointCAD studiesCardiology clinical trials
2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse eventsSex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies
Hussain Y, Kearney K, Abbott J, Kereiakes D, Di Mario C, Saito S, Cristea E, Riley R, Fajadet J, Shlofmitz R, Ali Z, Klein A, Price M, Hill J, Stone G, Lansky A. Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies. Journal Of The Society For Cardiovascular Angiography & Interventions 2022, 1: 100011. PMID: 39130137, PMCID: PMC11307712, DOI: 10.1016/j.jscai.2021.100011.Peer-Reviewed Original ResearchPrimary efficacy end pointPrimary safety end pointMajor adverse cardiovascular eventsAdverse cardiovascular eventsEfficacy end pointSafety end pointIntravascular lithotripsyEnd pointCardiovascular eventsMyocardial infarctionHospital major adverse cardiovascular eventsMean reference vessel diameterCoronary intravascular lithotripsySevere coronary calcificationCoronary artery calcificationReference vessel diameterPercutaneous coronary interventionPrior myocardial infarctionSex-based outcomesSex-specific outcomesSide branch involvementPatient-level analysisSmall vessel sizeAngiographic complicationsLesion predilatation
2016
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level data
2014
First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients
Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski Ł, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. Open Heart 2014, 1: e000064. PMID: 25332803, PMCID: PMC4189321, DOI: 10.1136/openhrt-2014-000064.Peer-Reviewed Original ResearchSecond-generation drug-eluting stentsPaclitaxel-eluting stentsDrug-eluting stentsSecond-generation EESCoronary artery diseaseMyocardial infarctionEnd pointArtery diseaseClinical trialsPrespecified safety end pointsStable coronary artery diseaseIncidence of MIFirst-generation drug-eluting stentsFirst-generation SESReduction of oddsEfficacy end pointSafety end pointTarget lesion revascularisationAcute coronary syndromeComposite end pointSafe drug-eluting stentCurrent clinical practiceLong-term safetyVessel revascularisationCardiac mortality
2012
Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years
Lansky AJ, Brar SS, Yaqub M, Sood P, Applegate RJ, Lazar D, Jankovic I, Hermiller JB, Koo K, Sudhir K, Stone GW. Impact of Routine Angiographic Follow-Up After Percutaneous Coronary Intervention With Drug-Eluting Stents in the SPIRIT III Randomized Trial at Three Years. The American Journal Of Cardiology 2012, 110: 21-29. PMID: 22464212, DOI: 10.1016/j.amjcard.2012.02.040.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, Balloon, CoronaryAntineoplastic Agents, PhytogenicCoronary AngiographyCoronary Artery DiseaseEverolimusFollow-Up StudiesHumansImmunosuppressive AgentsPaclitaxelProspective StudiesProsthesis DesignReproducibility of ResultsSingle-Blind MethodSirolimusTime FactorsTreatment OutcomeConceptsPaclitaxel-eluting stentsID-TLRAngiographic groupClinical followMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesDrug-eluting stent placementMajor adverse cardiovascular eventsBare metal stent implantationSPIRIT IIILandmark survival analysisSPIRIT III trialAdverse cardiovascular eventsSafety end pointCardiovascular event ratesIschemia-driven revascularizationMajor clinical outcomesPercutaneous coronary interventionDrug-eluting stentsRoutine AngiographicCardiovascular eventsCoronary revascularizationRevascularization ratesCoronary interventionIII trials
2011
Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction
Gibson CM, Maehara A, Lansky AJ, Wohrle J, Stuckey T, Dave R, Cox D, Grines C, Dudek D, Steg G, Parise H, Wolff SD, Cristea E, Stone GW. Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal 2011, 161: 478-486.e7. PMID: 21392601, DOI: 10.1016/j.ahj.2010.10.006.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAntithrombinsCoronary OcclusionCoronary ThrombosisEndpoint DeterminationHirudinsHumansImmunoglobulin Fab FragmentsInfusions, Intra-ArterialMagnetic Resonance Imaging, CineMyocardial InfarctionPatient SelectionPeptide FragmentsPlatelet Aggregation InhibitorsRecombinant ProteinsResearch DesignThrombectomyConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPrimary PCIAnterior ST-elevation myocardial infarctionExport aspiration catheterPercutaneous coronary interventionLocal infusionThrombus aspirationInfarct sizeINFUSE-AMIEnd pointCoronary interventionAspiration catheterMyocardial infarctionInfusion catheterAnterior ST-segment elevation myocardial infarctionST-segment elevation myocardial infarctionSingle-blind randomized studyCardiac magnetic resonance imagingMyocardial infarction 0Mid-left anteriorPrimary end pointSafety end pointSecondary end pointsST-segment resolution
2009
Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction
Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R. Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. New England Journal Of Medicine 2009, 360: 1946-1959. PMID: 19420364, DOI: 10.1056/nejmoa0810116.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngioplasty, Balloon, CoronaryCombined Modality TherapyCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsFemaleFibrinolytic AgentsFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelRecurrenceRetreatmentRiskStentsSwedenConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsElevation myocardial infarctionTarget lesion revascularizationMyocardial infarctionAngiographic evidenceEnd pointStent thrombosisIschemia-driven target lesion revascularizationPrimary PCIComposite safety end pointIdentical bare-metal stentMajor secondary end pointPrimary end pointSafety end pointSecondary end pointsTarget vessel revascularizationPercutaneous coronary interventionRepeat revascularization proceduresAcute myocardial infarctionSafety outcome measuresDrug-eluting stentsBinary restenosis
2005
Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis
Silber S, Popma JJ, Suntharalingam M, Lansky AJ, Heuser RR, Speiser B, Teirstein PS, Bass T, O'Neill W, Lasala J, Reisman M, Sharma SK, Kuntz RE, Bonan R, Investigators F. Two-year clinical follow-up of 90Sr/90 Y β-radiation versus placebo control for the treatment of in-stent restenosis. American Heart Journal 2005, 149: 689-694. PMID: 15990754, DOI: 10.1016/j.ahj.2004.05.061.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsBeta ParticlesBrachytherapyCoronary AngiographyCoronary DiseaseCoronary RestenosisDiabetes ComplicationsDisease-Free SurvivalFemaleFollow-Up StudiesHumansLife TablesMaleMiddle AgedPrognosisStentsStrontium RadioisotopesThrombophiliaTreatment OutcomeYttrium RadioisotopesConceptsMajor adverse cardiac eventsTarget vessel revascularizationStent restenosisIntracoronary brachytherapyOriginal patientsPrimary safety end pointTwo-year clinical outcomesPlacebo-controlled randomized trialEnd pointAdverse cardiac eventsPlacebo-controlled studyPrimary end pointSafety end pointKaplan-Meier analysisInitial beneficial effectsRestenosis TrialVessel revascularizationCardiac eventsPlacebo armClinical followActive treatmentClinical outcomesRandomized trialsPlacebo controlPatients